BioMed Central to publish clinical trial protocols to raise the standards of medical research

July 31, 2001

The publication of peer-reviewed protocols could potentially improve the standards of clinical trials by imposing scrutiny on research methods as well as having the additional benefit of boosting recruitment into trials.

By publishing protocols, BioMed Central is addressing a need identified by Iain Chalmers, director of the UK Cochrane Centre, and Doug Altman, of the ICRF Statistics Group in Oxford, for journals to play a more radical role in improving the standards of medical research. An editorial just published in BioMed Central ( details the ways in which publication of protocols will help to tackle what Altman has called the 'scandal of poor medical research'.

Briefly, the advantages of protocol publication are that it: The online journals within BioMed Central provide open peer review, rapid publication (with an average time from submission to publication of 6 weeks), unlimited space, worldwide barrier-free dissemination, and the ability to link protocols to recruitment initiatives, trial reports, full data sets, and systematic reviews. They also provide, through PubMed and PubMed Central, a searchable and permanent record of the protocol for citation.
To view examples of protocols published by BioMed Central visit: - A case control study of autism and MMR vaccination. - The CRASH trial, a multicentre randomised controlled trial of steroids in head injury.

BioMed Central

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to